Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-150 in Pain Caused by Small Fiber Neuropathy
2017-001042-10Phase 2Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jun 2017
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of VX-150 in small fiber neuropathy (SFN), Neuralgia, sponsored by Vertex Pharmaceuticals. Started Jun 2017; status: completed.
02
Drugs
VX-150
03
Conditions
small fiber neuropathy (SFN)Neuralgia
Beyond the preview
Go deeper on 2017-001042-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001042-10.